When ventricular fibrillation occurs in a ICU the first person reaching the client should?

Approach Considerations

Sustained ventricular tachycardia (VT) may lead to hemodynamic collapse. Consequently, these patients require urgent conversion to sinus rhythm. The strategy for conversion depends on whether the patient is hemodynamically stable or unstable.

Unstable patients have signs or symptoms of insufficient oxygen delivery to vital organs as a result of the tachycardia. Such manifestations may include the following:

• Dyspnea

• Hypotension

• Altered level of consciousness

In the workup, this situation must be differentiated from clinical manifestations of an underlying medical condition that is causing secondary tachycardia.

Unstable patients with monomorphic VT should be immediately treated with synchronized direct current (DC) cardioversion, usually at a starting energy dose of 100 J (monophasic; comparable biphasic recommendations are not currently available). Unstable polymorphic VT is treated with immediate defibrillation. The defibrillator may have difficulty recognizing the varying QRS complexes; therefore, synchronization of shocks may not occur.

Stable patients have adequate vital end-organ perfusion and thus do not experience signs or symptoms of hemodynamic compromise. Treatment depends on whether the VT is monomorphic or polymorphic and whether left ventricular (LV) function is normal or impaired (eg, reduced LV ejection fraction [LVEF], heart failure).

In stable patients with monomorphic VT and normal LV function, restoration of sinus rhythm is typically achieved with intravenous (IV) procainamide, amiodarone, or sotalol. Lidocaine may also be used, but this agent may have common and limiting side effects and, consequently, increase the overall mortality risk. A 12-lead electrocardiogram (ECG) is obtained before conversion.

If LV function is impaired, amiodarone (or lidocaine) is preferred to procainamide for pharmacologic conversion because of the latter drug’s potential for exacerbating heart failure. However, mounting evidence indicates that amiodarone should not be the first-line antiarrhythmic for stable VT, because its effects on myocardial conduction and refractoriness are gradual in onset. [52, 53, 54, 55] If medical therapy is unsuccessful, synchronized cardioversion (50-200 J monophasic) following sedation is appropriate.

Polymorphic VT in stable patients typically terminates on its own. However, it tends to recur. After sinus rhythm returns, the ECG should be analyzed to determine whether the QT interval is normal or prolonged. Polymorphic VT in patients with a normal QT interval is treated in the same manner as monomorphic VT.

If the patient has runs of polymorphic VT punctuated by sinus rhythm with QT prolongation, treatment is with magnesium sulfate, isoproterenol, pacing, or a combination thereof. Administration of phenytoin and lidocaine may also help by shortening the QT interval in this setting, but procainamide and amiodarone are contraindicated because of their QT-prolonging effects. Magnesium is unlikely to be effective in patients with a normal QT interval. [40]

In patients with electrolyte imbalances (eg, hypokalemia or hypomagnesemia from diuretic use), correction of the abnormality may be necessary for successful cardioversion. In patients with severe digitalis toxicity (eg, with sustained ventricular arrhythmias, advanced atrioventricular [AV] block, or asystole), treatment with anti-digitalis antibody may be indicated. [40]

After conversion of VT, the clinical emphasis shifts to determining the severity of heart disease, assessing the prognosis, and formulating the best long-term management plan. Options, depending on the severity of symptoms and degree of structural heart disease, include the following [9, 14] :

• Antiarrhythmic medications: Effective in reducing the arrhythmia burden but have no demonstrated mortality benefit [9] ; however, results from the Amiodarone, Lidocaine, or Placebo (ALPS) study indicate poor but not invariably fatal outcomes from the use of amiodarone or lidocaine for nonshockable (asystole/pulseless electric activity)-turned-shockable (ventricular fibrillation/VT) out-of-hospital cardiac arrest during resuscitation [56]

• Implantable cardioverter-defibrillator (ICD): Aids in the acute termination of ventricular arrhythmia and provides information on the long-term management of patients with VT [9]

• Catheter ablation: Effective, but recurrent VT is not uncommon [9, 57, 58]

Combinations of these therapies are often used when structural heart disease is present.

Antiarrhythmic drugs have traditionally been the mainstays of treatment for clinically stable patients with VT. However, some patients experience unacceptable side effects or frequent recurrence of VT with drug therapy. As a result, cardiologists are increasingly making use of devices and procedures designed to abort VT or to remove the dysrhythmogenic foci in the heart. In patients with idiopathic VT (associated with structurally normal hearts), medications are often avoided entirely through the use of curative catheter-based ablation.

Congenital long QT syndrome and catecholamine polymorphic VT have been linked to sudden cardiac death. Patients with these disorders are managed with a combination of genetic typing, beta blockers, lifestyle modification and, in selected cases, ICD placement. [59]

In the 1980s, several centers explored ventricular arrhythmia surgery, using excision and cryoablation of infarct zones to prevent recurrent VT. This strategy has been essentially abandoned as a consequence of its high mortality and the advent of ICDs and ablative therapies.

Select 2017 AHA/ACC/HRS recommendations

Select recommendations from the 2017 American Heart Association (AHA)/American College of Cardiology (ACC)/Heart Rhythm Society (HRS) guideline for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death include the following [44] :

• Patients with heart failure and reduced LVEF (≤40%): Administer a beta blocker, mineralocorticoid receptor antagonist, and either an angiotensin-converting enzyme inhibitor (ACEI) or an angiotensin-receptor blocker (ARB), or an angiotensin receptor-neprilysin inhibitor (ARNI) to reduce the risk of sudden cardiac death and all-cause mortality.

• Patients with ischemic heart disease and sustained monomorphic VT: More than coronary revascularization alone is needed to prevent recurrent VT.

• Patients with nonischemic cardiomyopathy, symptomatic heart failure (New York Heart Association [NYHA] class II-III symptoms), and an LVEF of 35% or below while on guideline-directed therapy: Place an ICD if the expected survival is longer than 1 year.

• Patients with previous MI and recurrent symptomatic sustained VT, or present with VT/VF storm, and are refractory to/intolerant of amiodarone: Perform catheter ablation.

• Patients requiring arrhythmia suppression for symptoms or declining ventricular function probably owing to frequent premature ventricular complexes for whom antiarrhythmics are not effective, tolerated, or preferred: Catheter ablation provides benefit.

Initial Supportive Management

Rapid transport to an emergency department (ED) is essential. Emergency medical service (EMS) personnel may be called upon to provide cardioversion/defibrillation in the field if they have sufficient training and if appropriate protocols exist.

EMS personnel must pay adequate attention to the primary survey and address airway, breathing, and circulation as necessary. Beyond those steps, vascular access, supplemental oxygen, and electrocardiographic rhythm strip monitoring are all-important, but they should not delay rapid transport to the ED for definitive care.

Cardioversion in Acute Ventricular Tachycardia

The acute emphasis in patients with ventricular tachycardia (VT) is on achieving an accurate diagnosis and conversion to sinus rhythm. VT associated with loss of consciousness or hypotension is a medical emergency necessitating immediate cardioversion. In a normal-sized adult, this is typically accomplished with a 100- to 200-J biphasic cardioversion shock administered according to standard Advanced cardiovascular life support (ACLS) protocols. [60, 61, 62]  Please refer to the most current ACLS guidelines, which are subject to periodic revision.

Reversible risk factors for VT should be addressed. Efforts should be made to correct hypokalemia and to withdraw any long-term medications associated with QT-interval prolongation.

When VT occurs in patients with ongoing myocardial ischemia, lidocaine is suggested as the primary antiarrhythmic medication, because the mechanism in these cases is thought to be abnormal automaticity rather than reentry. [63] Although intravenous (IV) lidocaine is effective at suppressing peri-infarction VT, it may increase the overall mortality risk. In situations involving torsade de pointes, magnesium sulfate may be effective if a long QT interval is present at baseline.

Synchronized cardioversion should be considered at an early stage if medical therapy fails to stabilize the rhythm. The initial shock energy should be 100 J (monophasic), followed by higher shock energies if the response is inadequate.

Occasionally, patients present with wide QRS complex tachycardia of unknown mechanism. In the absence of pacing, the differential diagnosis includes VT and aberrantly conducted supraventricular tachycardia (SVT) (see the images below). If hemodynamic compromise is present or if any doubt exists about the rhythm diagnosis, the safest strategy is to treat the rhythm as VT.

If the clinical situation permits, a 12-lead electrocardiogram (ECG) should be obtained before conversion of the rhythm. The ECG criteria of Brugada et al [15] may be useful in differentiating the arrhythmia mechanism (see Workup).

Rarely, patients present with repetitive runs of nonsustained VT. Prolonged exposure to this (or any other) tachycardia may cause a tachycardia-induced cardiomyopathy, which typically improves with medical or ablative treatment of the VT. [19]

Pulseless VT

Pulseless VT, in contrast to other unstable VT rhythms, is treated with immediate defibrillation. High-dose unsynchronized energy should be used. The initial shock dose on a biphasic defibrillator is 150-200 J, followed by an equal or higher shock dose for subsequent shocks. If a monophasic defibrillator is used, the initial and subsequent shock dose should be 360 J.

Shock administration should be followed by immediate chest compressions, airway management with supplemental oxygen, and vascular access with administration of vasopressors. In cases of shock-resistant pulseless VT, the use of antiarrhythmic medications may be considered. IV amiodarone is the drug of choice.

Vasopressors can include epinephrine 1 mg IV given every 3-5 minutes or, in lieu of epinephrine, vasopressin 40 units IV as a 1-time dose. [64]  

Poststabilization Management

After initial treatment and stabilization, patients with ventricular tachycardia (VT) generally should undergo the following:

• Referral to a cardiologist

• Admission to a monitored bed

• Further studies, such as electrophysiologic study (EPS)

• Consideration for radiofrequency ablation (RFA)

• Consideration for ICD placement

Initiation of antiarrhythmic medications may require telemetry monitoring for drug-induced proarrhythmia. Patients starting class IA and class III drugs should be monitored for corrected QT (QTc) prolongation and torsade de pointes until steady-state drug levels (≥5 clearance half-lives) have been reached. A notable exception is amiodarone, which may require months to achieve steady state; drug loading of amiodarone is necessarily completed on an outpatient basis. [55]

Class IC antiarrhythmics are associated with drug-induced VT and rate-related conduction slowing. Many centers commit their patients to telemetry monitoring and predischarge exercise testing during initiation of agents from this class. Sinus bradycardia and sinus node dysfunction are often exacerbated by antiarrhythmic drugs.

Adult patients with ventricular arrhythmias whose age, sex, and symptoms indicate a moderate or greater likelihood of coronary heart disease, should undergo exercise testing to provoke ischemic changes or ventricular arrhythmias. [40] Regardless of age, exercise testing is useful in patients with established or suspected exercise-induced ventricular arrhythmias, including catecholaminergic VT, to provoke the arrhythmia, to confirm a diagnosis, and to ascertain the patient’s response to tachycardia. [40]

Long-Term Treatment

Patients with monomorphic ventricular tachycardia (VT) who have structurally normal hearts are at a low risk of sudden death. Consequently, implantable cardioverter-defibrillators (ICDs) are rarely necessary in this setting; these patients are almost always managed with medications or ablation.

Antiarrhythmic drug trials have been disappointing, particularly in patients with left ventricular dysfunction. Some antiarrhythmic drugs may actually increase sudden-death mortality in this group. This is a particular concern with Vaughan Williams class I antiarrhythmics, which slow propagation and reduce tissue excitability through sodium-channel blockade. For most patients with left ventricular dysfunction, current clinical practice favors class III antiarrhythmics, which prolong myocardial repolarization through potassium-channel blockade. [65]

Amiodarone is a complex antiarrhythmic drug that deserves special mention. It is generally listed as a class III agent but has measurable class I, II, and IV effects. Unlike class I antiarrhythmics, amiodarone appears to be safe in patients with left ventricular dysfunction.

Amiodarone, when used in combination with beta blockers, can be useful for patients with left ventricular dysfunction due to previous myocardial infarction (MI) and symptoms due to VT that do not respond to beta blockers. [40]

In the Electrophysiologic Study versus Electrocardiographic Monitoring (ESVEM) trial, which compared long-term treatment with seven antiarrhythmic drugs (not including amiodarone) in patients with VT, the risks of adverse drug effects, arrhythmia recurrence, or death from any cause were lowest with sotalol. [65] The other antiarrhythmic drugs studied in the ESVEM trial were imipramine, mexiletine, pirmenol, procainamide, propafenone, and quinidine.

In patients with heart failure, the best-proven—albeit nonspecific—antiarrhythmic drug strategies include the use of the following:

• The beta receptor–blocking drugs carvedilol, metoprolol, and bisoprolol

• Angiotensin-converting enzyme (ACE) inhibitors

• Aldosterone antagonists

Statin therapy is advantageous in patients with coronary heart disease, to reduce the risk of vascular accidents, ventricular arrhythmias (possibly), and sudden cardiac death. [40]

Although idiopathic VTs often respond to verapamil, this agent may cause hemodynamic collapse and death when administered to treat VT in patients with left ventricular dysfunction. Therefore, verapamil (or any other calcium-channel blockers) is contraindicated in any patient with wide-complex tachycardia of uncertain etiology. [54]

Catheter Ablation

Radiofrequency ablation (RFA) via endocardial or epicardial catheter placement can be used to treat ventricular tachycardia (VT) in patients with left ventricular dysfunction from previous myocardial infarction (MI), [66] cardiomyopathy, bundle-branch reentry, and various forms of idiopathic VT (see the image below). [40]  RFA is often used in conjunction with implantable cardioverter-defibrillator (ICD) therapy in the presence of recurrent VT episodes to reduce the frequency of required ICD therapies. [40] For patients with structural heart disease, it is currently uncertain whether VT ablation obviates other therapies, such as placement of an ICD). [5, 6, 7, 8]

Current techniques include three-dimensional scar, late potential, and activation mapping, followed by high-energy RFA with irrigated-tip catheters capable of creating deeper lesions in the thicker left ventricular wall. In some patients, percutaneous epicardial ablation can be used successfully when endocardial lesions fail. [67, 68]

Catheter ablation is used early in patients with idiopathic monomorphic VT (ie, VT in a structurally normal heart arising from a focal source) that is resistant to drug therapy, as well as in those who are drug-intolerant or do not wish to have long-term drug therapy. [40] In these patients, ablation is used to treat symptoms rather than to reduce the risk of sudden death. In patients with structurally normal hearts, catheter ablation can eliminate symptomatic VT arising from the right or left ventricle.

Catheter ablation may also be used in patients with cardiomyopathy. The goal in these cases is to reduce the arrhythmia burden and thereby minimize the number of ICD shocks.

Ablation is also used in patients with bundle-branch reentrant VT. [40] Most ischemic reentrant VT requires a slow conduction zone, which is usually located along the border of a scarred zone of myocardium. The small physical size of the slow conduction zone makes it an ideal target for focal ablation procedures. Cell disruption can be achieved by using RFA or cryoablation via transvenous catheters during closed-chest procedures.

Kumar et al assessed the long-term prognosis after ablation for sustained VT in 695 consecutive patients with no structural heart disease (no SHD, n = 98), ischemic cardiomyopathy (ICM, n = 358), or nonischemic cardiomyopathy (NICM, n = 239). At a median follow-up of 6 years, ventricular arrhythmia (VA)-free survival was highest in patients with no SHD (77%), followed by patients with ICM (54%) and patients with NICM (38%); overall survival was highest in patients with no SHD (100%), followed by patients with NICM (74%) and patients with ICM (48%). [69]

In a study of 2061 patients with scar-related VT, Tung et al found that patients who experience no VT recurrence after catheter ablation have an increased rate of transplant-free survival. [70]  The investigators determined that following ablation, 70% of the study’s patients, who suffered from ischemic or nonischemic cardiomyopathy, were free from VT recurrence for 1 year, with 90% cardiac transplantation-free survival  at 1 year in those without VT recurrence, compared with 71% in patients with recurrence. [70]

In a two-center study that examined the use of a percutaneous left ventricular assist device (pLVAD) in patients undergoing ablation for scar-related VT, use of a pLVAD allowed maintenance in VT for a significantly longer period by virtue of its ability to maintain end-organ perfusion. [71]  Whether this effect will translate into clinical benefits is unclear. At the least, however, this study demonstrates the benefit of pLVADs in patients with scar-related unstable VT.

Because patients with ischemic VT often have multiple reentrant circuits, ablation is typically used as an adjunct to ICD therapy. If VT arises from an automatic focus, the focus can be targeted for ablation.

In patients with structurally normal hearts, the most common form of VT arises from the right ventricular outflow tract (RVOT). The typical outflow tract ectopic beat shows a positive QRS axis in the inferior leads. Abnormal or triggered automaticity is the most likely mechanism, and focal ablation is curative in these patients. Ablation cure rates typically exceed 95% if the arrhythmia can be induced in the electrophysiology laboratory. Difficulty of outflow tract ablation may be predicted by ECG morphology. [72]

Reentrant tachycardia may arise from the RVOT in patients with right ventricular dysplasia or repaired tetralogy of Fallot. These circuits are usually amenable to catheter ablation (see the image below). [73, 74]

In a study that evaluated the long-term safety and effectiveness of irrigated radiofrequency catheter ablation in 249 patients with sustained monomorphic VT associated with coronary disease, 75.9% achieved noninducibility of targeted VT. [75] The results showed that RFA reduced ICD shocks and VT episodes and improved quality of life at 6 months; improved long-term outcomes included a steady 3-year nonrecurrence rate with reduced amiodarone use and hospitalizations. [75]

In a prospective study to assess the incidence and predictors of major complications from contemporary catheter ablation procedures, major complication rates ranged from 0.8% (SVT) to 6% (VT associated with structural heart disease), depending on the ablation procedure performed. [76]  Renal insufficiency was the only independent predictor of a major complication.

Implantable Cardioverter-Defibrillator Placement

The advent of the  implantable cardioverter-defibrillator (ICD) has changed the face of ventricular arrhythmia management. Like pacemakers, these devices can be implanted transvenously in a brief, low-risk procedure. Once implanted, the ICD can detect ventricular tachyarrhythmias and terminate them with defibrillation shocks or anti-tachycardia pacing algorithms (see the image below).

ICD therapy is used to augment medical management for the following individuals [4] :

• Most patients with hemodynamically unstable VT

• Most patients with prior myocardial infarction (MI) and hemodynamically stable sustained VT

• Most cardiomyopathy patients with unexplained syncope (an arrhythmia is presumed)

• Most patients with genetic sudden death syndromes when unexplained syncope is noted

In patients with prior VT or ventricular fibrillation (VF), the Antiarrhythmics Versus Implantable Defibrillators (AVID) study, the Canadian Implantable Defibrillator Study (CIDS), and the Cardiac Arrest Study, Hamburg (CASH), demonstrated better survival with ICD therapy than with antiarrhythmic therapy with amiodarone or sotalol. [77] The survival difference was statistically significant in AVID, of borderline significance in CIDS, and insignificant in CASH. A meta-analysis of the three trials found a 28% reduction in relative risk of death. [77]

Patients with nonischemic dilated cardiomyopathy and considerable left ventricular dysfunction, or arrhythmogenic right ventricular cardiomyopathy, who have sustained VT or VF should have ICD placement. These patients should also be receiving optimal long-term medical therapy and may reasonably be expected to survive with good functional status for longer than 1 year. [4]

ICDs are not used for the following individuals [46] :

• Patients with VT or VF occurring during an acute ST-segment elevation MI (STEMI)

• Patients with reversible, drug-induced VT

• Patients with poor expected survival as a consequence of comorbid conditions

Because ICDs treat, rather than prevent, ventricular arrhythmias, as many as 50% of ICD recipients require therapy with antiarrhythmic drugs to reduce the potential for ICD shocks. Catheter ablation may be used in patients with an ICD who are receiving multiple shocks because of sustained VT that is not manageable by changing drug therapy or who do not wish to undergo long-term drug therapy. [40]

Prospective follow-up data from 2,352 patients in the Israeli ICD Registry suggest that the presence of anemia (hemoglobin [Hb] ≤12 g/dL) in patients with ICDs independently increases the risk for ventricular arrhythmias during long-term follow-up. [78]  At 2.5 years of follow-up, the rate of appropriate shocks in patients with low Hb levels (11%) was nearly double that of those with high Hb levels (6%) (log-rank P <0.005). Moreover, each 1 g/dL reduction in Hb was independently associated with a significant 8% increased risk for a first appropriate shock (P <0.03), and anemia increased the risk for all-cause mortality as well as heart failure hospitalizations or death, but not with inappropriate ICD shocks. [78]

Diet and Activity

Patients with ischemic ventricular tachycardia (VT) may benefit from low-cholesterol diets, low-salt diets, or both. Patients with idiopathic VT may notice a reduction in symptoms when stimulants (eg, caffeine) are avoided. [79] Fish oil supplementation does not reduce the risk of VT or VF in patients with implantable cardioverter-defibrillator (ICD) and a recent sustained ventricular arrhythmia. [80]

VT may be precipitated by increased sympathetic tone during strenuous physical exertion. A goal of successful VT management is to allow the patient to return to an active lifestyle through medications, ICD implantation, ablation therapy, or some combination thereof.

Smoking should be strongly discouraged in all patients who have, or who are thought to have, ventricular arrhythmias, aborted sudden cardiac death (SCD), or both. Cigarette smoking is an independent risk factor for SCD, typically from arrhythmia and regardless of underlying coronary heart disease; smoking cessation significantly reduces the risk of SCD. [40]

Consultations

Patients with ventricular tachycardia (VT) should be referred to general cardiologists or electrophysiologists for specialized care. Cardiac electrophysiology is a subspecialty devoted to the diagnosis and management of cardiac arrhythmias.

In rare cases, a patient with a stable, recurrent episode of VT that is controlled in the emergency department can be discharged rather than admitted, provided that appropriate follow-up care is available. However, this decision must be made in consultation with a cardiologist.

Long-Term Monitoring

Outpatient medication choices for patients with ventricular tachycardia (VT) depend on the degree of ventricular dysfunction, the presence or absence of an an implantable cardioverter-defibrillator (ICD), and the presence or absence of comorbid disease, such as asthma. Continued therapy for underlying heart failure or coronary artery disease (CAD) remains important.

Patients receiving long-term antiarrhythmic therapy should be observed regularly for proarrhythmia and adverse effects. Patients should be questioned carefully about recurrent palpitations and syncope. Adverse reactions may be observed at any time during the course of drug therapy. The risk of amiodarone-induced liver, lung, thyroid, and other toxicities has prompted publication of specific follow-up testing guidelines. [40]

Sotalol and dofetilide are loaded on an inpatient basis, with telemetry and electrocardiographic (ECG) monitoring during 5-6 drug half-lives for bradycardia, ventricular proarrhythmia, and excessive QT prolongation. Many centers then follow sotalol-receiving patients on a quarterly basis to reassess renal function, observe QT intervals, and watch for new drug interactions. Patients with frequent VT episodes (“storm”) receiving amiodarone also commonly receive at least an initial load during an inpatient status via an intravenous route.

When VT is observed in a patient receiving an antiarrhythmic drug, it is essential to distinguish between VT recurrence and drug-induced ventricular proarrhythmia. The most common malignant form of proarrhythmia is torsade de pointes associated with QT-interval prolongation, usually due to excessive potassium-channel blockade.

The possibility of drug-specific noncardiac adverse effects warrants special vigilance. For example, flecainide can cause visual disturbances. Procainamide can cause joint pains and (with long-term use) a lupus syndrome.

Patients with ICDs require regular outpatient device follow-up to allow monitoring of battery and transvenous lead status. Although battery lifetime is somewhat predictable, lead fracture and failure may occur at any time. Lead problems can generally be diagnosed in the clinic and occasionally necessitate lead revision or replacement.

In addition, the efficacy of the ICD should be rechecked after the initiation of medications that may increase the ventricular defibrillation threshold. This is typically accomplished by means of an outpatient noninvasive programmed stimulation study (NIPS) carried out through the implanted device.

Patients who have experienced polymorphic VT in association with a prolonged QT interval as a result of antiarrhythmic agents or other drugs should be cautioned to avoid exposure to all agents associated with QT prolongation. A list of such agents can be found at the Arizona Center for Education and Research on Therapeutics (AZCERT) website.

1. Tang PT, Shenasa M, Boyle NG. Ventricular arrhythmias and sudden cardiac death. Card Electrophysiol Clin. 2017 Dec. 9 (4):693-708. [QxMD MEDLINE Link].

2. McNally B, Robb R, Mehta M, Vellano K, Valderrama AL, Yoon PW, et al. Out-of-hospital cardiac arrest surveillance --- Cardiac Arrest Registry to Enhance Survival (CARES), United States, October 1, 2005--December 31, 2010. MMWR Surveill Summ. 2011 Jul 29. 60 (8):1-19. [QxMD MEDLINE Link]. [Full Text].

3. Ellenbogen KA, Wan C, Shavelle DM. Outcome of patients with in-hospital ventricular tachycardia and ventricular fibrillation arrest while using a wearable cardioverter defibrillator. Am J Cardiol. 2017 Nov 16. [QxMD MEDLINE Link].

4. [Guideline] Russo AM, Stainback RF, Bailey SR, et al. ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCMR 2013 appropriate use criteria for implantable cardioverter-defibrillators and cardiac resynchronization therapy: a report of the American College of Cardiology Foundation appropriate use criteria task force, Heart Rhythm Society, American Heart Association, American Society of Echocardiography, Heart Failure Society of America, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society for Cardiovas... J Am Coll Cardiol. 2013 Mar 26. 61(12):1318-68. [QxMD MEDLINE Link]. [Full Text].

5. Macintyre CJ, Sapp JL. Catheter ablation for ventricular tachycardia in structural heart disease. Can J Cardiol. 2014 Feb. 30 (2):244-6. [QxMD MEDLINE Link].

6. Maury P, Baratto F, Zeppenfeld K, et al. Radio-frequency ablation as primary management of well-tolerated sustained monomorphic ventricular tachycardia in patients with structural heart disease and left ventricular ejection fraction over 30%. Eur Heart J. 2014 Jun 7. 35 (22):1479-85. [QxMD MEDLINE Link].

7. Hadid C. Sustained ventricular tachycardia in structural heart disease. Cardiol J. 2015. 22 (1):12-24. [QxMD MEDLINE Link].

8. Tung R, Vaseghi M, Frankel DS, et al. Freedom from recurrent ventricular tachycardia after catheter ablation is associated with improved survival in patients with structural heart disease: An International VT Ablation Center Collaborative Group study. Heart Rhythm. 2015 Sep. 12 (9):1997-2007. [QxMD MEDLINE Link].

9. Dresen WF, Ferguson JD. Ventricular arrhythmias. Cardiol Clin. 2018 Feb. 36 (1):129-39. [QxMD MEDLINE Link].

10. Rassi A Jr, Rassi A, Rassi SG. Predictors of mortality in chronic Chagas disease: a systematic review of observational studies. Circulation. 2007 Mar 6. 115 (9):1101-8. [QxMD MEDLINE Link].

11. Brugada J, Brugada R, Brugada P. Channelopathies: a new category of diseases causing sudden death. Herz. 2007 May. 32 (3):185-91. [QxMD MEDLINE Link].

12. SippensGroenewegen A, Spekhorst H, van Hemel NM, et al. Localization of the site of origin of postinfarction ventricular tachycardia by endocardial pace mapping. Body surface mapping compared with the 12-lead electrocardiogram. Circulation. 1993 Nov. 88 (5 Pt 1):2290-306. [QxMD MEDLINE Link].

13. Haqqani HM, Morton JB, Kalman JM. Using the 12-lead ECG to localize the origin of atrial and ventricular tachycardias: part 2--ventricular tachycardia. J Cardiovasc Electrophysiol. 2009 Jul. 20 (7):825-32. [QxMD MEDLINE Link].

14. Tilz RR, Lenarczyk R, Scherr D, et al. Management of ventricular tachycardia in the ablation era: results of the European Heart Rhythm Association Survey. Europace. 2017 Nov 23. [QxMD MEDLINE Link].

15. Brugada P, Brugada J, Mont L, Smeets J, Andries EW. A new approach to the differential diagnosis of a regular tachycardia with a wide QRS complex. Circulation. 1991 May. 83 (5):1649-59. [QxMD MEDLINE Link].

16. Vereckei A, Duray G, Szénási G, Altemose GT, Miller JM. New algorithm using only lead aVR for differential diagnosis of wide QRS complex tachycardia. Heart Rhythm. 2008 Jan. 5 (1):89-98. [QxMD MEDLINE Link].

17. Kannankeril PJ, Roden DM. Drug-induced long QT and torsade de pointes: recent advances. Curr Opin Cardiol. 2007 Jan. 22 (1):39-43. [QxMD MEDLINE Link].

18. Turker Y, Ozaydin M, Acar G, et al. Predictors of ventricular arrhythmias in patients with mitral valve prolapse. Int J Cardiovasc Imaging. 2010 Feb. 26 (2):139-45. [QxMD MEDLINE Link].

19. Yarlagadda RK, Iwai S, Stein KM, et al. Reversal of cardiomyopathy in patients with repetitive monomorphic ventricular ectopy originating from the right ventricular outflow tract. Circulation. 2005 Aug 23. 112 (8):1092-7. [QxMD MEDLINE Link].

20. Yokokawa M, Kim HM, Good E, et al. Relation of symptoms and symptom duration to premature ventricular complex-induced cardiomyopathy. Heart Rhythm. 2012 Jan. 9 (1):92-5. [QxMD MEDLINE Link].

21. Tsatsopoulou AA, Protonotarios NI, McKenna WJ. Arrhythmogenic right ventricular dysplasia, a cell adhesion cardiomyopathy: insights into disease pathogenesis from preliminary genotype--phenotype assessment. Heart. 2006 Dec. 92 (12):1720-3. [QxMD MEDLINE Link]. [Full Text].

22. Nademanee K, Veerakul G, Mower M, et al. Defibrillator versus beta-blockers for unexplained death in Thailand (DEBUT): a randomized clinical trial. Circulation. 2003 May 6. 107 (17):2221-6. [QxMD MEDLINE Link].

23. Liberthson RR. Sudden death from cardiac causes in children and young adults. N Engl J Med. 1996 Apr 18. 334 (16):1039-44. [QxMD MEDLINE Link].

24. Yoon G, Quitania L, Kramer JH, Fu YH, Miller BL, Ptacek LJ. Andersen-Tawil syndrome: definition of a neurocognitive phenotype. Neurology. 2006 Jun 13. 66 (11):1703-10. [QxMD MEDLINE Link].

25. Splawski I, Timothy KW, Sharpe LM, et al. Ca(V)1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. Cell. 2004 Oct 1. 119 (1):19-31. [QxMD MEDLINE Link].

26. Priori SG, Napolitano C, Memmi M, et al. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Circulation. 2002 Jul 2. 106 (1):69-74. [QxMD MEDLINE Link].

27. Lopes LR, Zekavati A, Syrris P, et al. Genetic complexity in hypertrophic cardiomyopathy revealed by high-throughput sequencing. J Med Genet. 2013 Apr. 50 (4):228-39. [QxMD MEDLINE Link]. [Full Text].

28. Pilichou K, Nava A, Basso C, et al. Mutations in desmoglein-2 gene are associated with arrhythmogenic right ventricular cardiomyopathy. Circulation. 2006 Mar 7. 113 (9):1171-9. [QxMD MEDLINE Link].

29. Ohno S. The genetic background of arrhythmogenic right ventricular cardiomyopathy. J Arrhythm. 2016 Oct. 32 (5):398-403. [QxMD MEDLINE Link]. [Full Text].

30. Letsas KP, Weber R, Astheimer K, Kalusche D, Arentz T. Tpeak-Tend interval and Tpeak-Tend/QT ratio as markers of ventricular tachycardia inducibility in subjects with Brugada ECG phenotype. Europace. 2010 Feb. 12 (2):271-4. [QxMD MEDLINE Link].

31. Mademont-Soler I, Pinsach-Abuin ML, Riuro H, et al. Large genomic imbalances in Brugada syndrome. PLoS One. 2016. 11 (9):e0163514. [QxMD MEDLINE Link]. [Full Text].

32. Lerman BB, Dong B, Stein KM, Markowitz SM, Linden J, Catanzaro DF. Right ventricular outflow tract tachycardia due to a somatic cell mutation in G protein subunitalphai2. J Clin Invest. 1998 Jun 15. 101 (12):2862-8. [QxMD MEDLINE Link]. [Full Text].

33. Chugh SS, Jui J, Gunson K, et al. Current burden of sudden cardiac death: multiple source surveillance versus retrospective death certificate-based review in a large U.S. community. J Am Coll Cardiol. 2004 Sep 15. 44 (6):1268-75. [QxMD MEDLINE Link].

34. Garson A Jr, Gillette PC, McNamara DG. Supraventricular tachycardia in children: clinical features, response to treatment, and long-term follow-up in 217 patients. J Pediatr. 1981 Jun. 98 (6):875-82. [QxMD MEDLINE Link].

35. Gordon T, Kannel WB. Premature mortality from coronary heart disease. The Framingham study. JAMA. 1971 Mar 8. 215 (10):1617-25. [QxMD MEDLINE Link].

36. Kosmidou I, Embacher M, McAndrew T, et al. Early ventricular tachycardia or fibrillation in patients with ST elevation myocardial infarction undergoing primary percutaneous coronary intervention and impact on mortality and stent thrombosis (from the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction Trial). Am J Cardiol. 2017 Nov 15. 120 (10):1755-60. [QxMD MEDLINE Link].

37. Turakhia M, Tseng ZH. Sudden cardiac death: epidemiology, mechanisms, and therapy. Curr Probl Cardiol. 2007 Sep. 32 (9):501-46. [QxMD MEDLINE Link].

38. Wolpert C, Schimpf R, Veltmann C, Giustetto C, Gaita F, Borggrefe M. Clinical characteristics and treatment of short QT syndrome. Expert Rev Cardiovasc Ther. 2005 Jul. 3 (4):611-7. [QxMD MEDLINE Link].

39. Patel U, Pavri BB. Short QT syndrome: a review. Cardiol Rev. 2009 Nov-Dec. 17 (6):300-3. [QxMD MEDLINE Link].

40. [Guideline] Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol. 2006 Sep 5. 48(5):e247-346. [QxMD MEDLINE Link].

41. Marill KA, Wolfram S, Desouza IS, et al. Adenosine for wide-complex tachycardia: efficacy and safety. Crit Care Med. 2009 Sep. 37 (9):2512-8. [QxMD MEDLINE Link].

42. Ventricular tachycardia management in the adult. Family Practice Notebook. Available at http://www.fpnotebook.com/CV/EKG/VntrclrTchycrdMngmntInThAdlt.htm. Accessed: December 4, 2017.

43. Garmel GM. Wide complex tachycardias: understanding this complex condition part 2 - management, miscellaneous causes, and pitfalls. West J Emerg Med. 2008 May. 9 (2):97-103. [QxMD MEDLINE Link]. [Full Text].

44. [Guideline] Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2017 Oct 30. [QxMD MEDLINE Link].

45. Arya A, Piorkowski C, Sommer P, Gerds-Li JH, Kottkamp H, Hindricks G. Idiopathic outflow tract tachycardias: current perspectives. Herz. 2007 May. 32 (3):218-25. [QxMD MEDLINE Link].

46. Segal OR, Chow AW, Wong T, et al. A novel algorithm for determining endocardial VT exit site from 12-lead surface ECG characteristics in human, infarct-related ventricular tachycardia. J Cardiovasc Electrophysiol. 2007 Feb. 18 (2):161-8. [QxMD MEDLINE Link].

47. Josephson ME, Callans DJ. Using the twelve-lead electrocardiogram to localize the site of origin of ventricular tachycardia. Heart Rhythm. 2005 Apr. 2 (4):443-6. [QxMD MEDLINE Link].

48. Noda T, Shimizu W, Taguchi A, et al. Malignant entity of idiopathic ventricular fibrillation and polymorphic ventricular tachycardia initiated by premature extrasystoles originating from the right ventricular outflow tract. J Am Coll Cardiol. 2005 Oct 4. 46 (7):1288-94. [QxMD MEDLINE Link].

49. Wellens HJ, Bar FW, Lie KI. The value of the electrocardiogram in the differential diagnosis of a tachycardia with a widened QRS complex. Am J Med. 1978 Jan. 64 (1):27-33. [QxMD MEDLINE Link].

50. Avanesov M, Munch J, Weinrich J, et al. Prediction of the estimated 5-year risk of sudden cardiac death and syncope or non-sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy using late gadolinium enhancement and extracellular volume CMR. Eur Radiol. 2017 Dec. 27 (12):5136-45. [QxMD MEDLINE Link].

51. Nam GB, Ko KH, Kim J, et al. Mode of onset of ventricular fibrillation in patients with early repolarization pattern vs. Brugada syndrome. Eur Heart J. 2010 Feb. 31 (3):330-9. [QxMD MEDLINE Link]. [Full Text].

52. Tomlinson DR, Cherian P, Betts TR, Bashir Y. Intravenous amiodarone for the pharmacological termination of haemodynamically-tolerated sustained ventricular tachycardia: is bolus dose amiodarone an appropriate first-line treatment?. Emerg Med J. 2008 Jan. 25 (1):15-8. [QxMD MEDLINE Link].

53. Buxton AE, Marchlinski FE, Doherty JU, Flores B, Josephson ME. Hazards of intravenous verapamil for sustained ventricular tachycardia. Am J Cardiol. 1987 May 1. 59 (12):1107-10. [QxMD MEDLINE Link].

54. Turley AJ, Thambyrajah J, Harcombe AA. Bilateral thoracoscopic cervical sympathectomy for the treatment of recurrent polymorphic ventricular tachycardia. Heart. 2005 Jan. 91 (1):15-7. [QxMD MEDLINE Link]. [Full Text].

55. [Guideline] Epstein AE, Olshansky B, Naccarelli GV, Kennedy JI Jr, Murphy EJ, Goldschlager N. Practical management guide for clinicians who treat patients with amiodarone. Am J Med. 2016 May. 129 (5):468-75. [QxMD MEDLINE Link].

56. Kudenchuk PJ, Leroux BG, Daya M, et al, for the Resuscitation Outcomes Consortium Investigators. Antiarrhythmic drugs for nonshockable-turned-shockable out-of-hospital cardiac arrest: the ALPS study (Amiodarone, Lidocaine, or Placebo). Circulation. 2017 Nov 28. 136 (22):2119-31. [QxMD MEDLINE Link].

57. Stevenson WG, Soejima K. Catheter ablation for ventricular tachycardia. Circulation. 2007 May 29. 115 (21):2750-60. [QxMD MEDLINE Link].

58. Nagashima K, Choi EK, Tedrow UB, et al. Correlates and prognosis of early recurrence after catheter ablation for ventricular tachycardia due to structural heart disease. Circ Arrhythm Electrophysiol. 2014 Oct. 7 (5):883-8. [QxMD MEDLINE Link].

59. Farwell D, Gollob MH. Electrical heart disease: Genetic and molecular basis of cardiac arrhythmias in normal structural hearts. Can J Cardiol. 2007 Aug. 23 suppl A:16A-22A. [QxMD MEDLINE Link]. [Full Text].

60. [Guideline] Link MS, Berkow LC, Kudenchuk PJ, et al. Part 7: Adult advanced cardiovascular life support: 2015 American Heart Association guidelines update for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2015 Nov 3. 132 (18 suppl 2):S444-64. [QxMD MEDLINE Link]. [Full Text].

61. [Guideline] Soar J, Callaway CW, Aibiki M, et al, for the Advanced Life Support Chapter Collaborators. Part 4: Advanced life support: 2015 International consensus on cardiopulmonary resuscitation and emergency cardiovascular care science with treatment recommendations. Resuscitation. 2015 Oct. 95:e71-120. [QxMD MEDLINE Link]. [Full Text].

62. [Guideline] Soar J, Nolan JP, Böttiger BW, et al, for the Adult advanced life support section Collaborators. European Resuscitation Council guidelines for resuscitation 2015: Section 3. Adult advanced life support. Resuscitation. 2015 Oct. 95:100-47. [QxMD MEDLINE Link]. [Full Text].

63. Marill KA, deSouza IS, Nishijima DK, et al. Amiodarone or procainamide for the termination of sustained stable ventricular tachycardia: an historical multicenter comparison. Acad Emerg Med. 2010 Mar. 17(3):297-306. [QxMD MEDLINE Link].

64. Callaway CW. Epinephrine for cardiac arrest. Curr Opin Cardiol. 2013 Jan. 28 (1):36-42. [QxMD MEDLINE Link].

65. Mason JW. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. Electrophysiologic Study versus Electrocardiographic Monitoring Investigators. N Engl J Med. 1993 Aug 12. 329 (7):452-8. [QxMD MEDLINE Link].

66. Arenal A, Hernandez J, Calvo D, et al. Safety, long-term results, and predictors of recurrence after complete endocardial ventricular tachycardia substrate ablation in patients with previous myocardial infarction. Am J Cardiol. 2013 Feb 15. 111 (4):499-505. [QxMD MEDLINE Link].

67. Sosa E, Scanavacca M, D'Avila A, et al. Endocardial and epicardial ablation guided by nonsurgical transthoracic epicardial mapping to treat recurrent ventricular tachycardia. J Cardiovasc Electrophysiol. 1998 Mar. 9 (3):229-39. [QxMD MEDLINE Link].

68. Tung R, Michowitz Y, Yu R, et al. Epicardial ablation of ventricular tachycardia: an institutional experience of safety and efficacy. Heart Rhythm. 2013 Apr. 10 (4):490-8. [QxMD MEDLINE Link].

69. Kumar S, Romero J, Mehta NK, et al. Long-term outcomes after catheter ablation of ventricular tachycardia in patients with and without structural heart disease. Heart Rhythm. 2016 Oct. 13 (10):1957-63. [QxMD MEDLINE Link].

70. Tung R, Vaseghi M, Frankel DS, et al. Freedom from recurrent ventricular tachycardia after catheter ablation is associated with improved survival in patients with structural heart disease: An International VT Ablation Center Collaborative Group study. Heart Rhythm. 2015 Sep. 12 (9):1997-2007. [QxMD MEDLINE Link].

71. Miller MA, Dukkipati SR, Mittnacht AJ, et al. Activation and entrainment mapping of hemodynamically unstable ventricular tachycardia using a percutaneous left ventricular assist device. J Am Coll Cardiol. 2011 Sep 20. 58 (13):1363-71. [QxMD MEDLINE Link].

72. Mallidi J, Nadkarni GN, Berger RD, Calkins H, Nazarian S. Meta-analysis of catheter ablation as an adjunct to medical therapy for treatment of ventricular tachycardia in patients with structural heart disease. Heart Rhythm. 2011 Apr. 8 (4):503-10. [QxMD MEDLINE Link]. [Full Text].

73. Khairy P, Stevenson WG. Catheter ablation in tetralogy of Fallot. Heart Rhythm. 2009 Jul. 6 (7):1069-74. [QxMD MEDLINE Link].

74. Hachiya H, Hirao K, Sasaki T, et al. Novel ECG predictor of difficult cases of outflow tract ventricular tachycardia: peak deflection index on an inferior lead. Circ J. 2010 Feb. 74 (2):256-61. [QxMD MEDLINE Link].

75. Marchlinski FE, Haffajee CI, Beshai JF, et al. Long-term success of irrigated radiofrequency catheter ablation of sustained ventricular tachycardia: post-approval THERMOCOOL VT trial. J Am Coll Cardiol. 2016 Feb 16. 67 (6):674-83. [QxMD MEDLINE Link].

76. Bohnen M, Stevenson WG, Tedrow UB, et al. Incidence and predictors of major complications from contemporary catheter ablation to treat cardiac arrhythmias. Heart Rhythm. 2011 Nov. 8 (11):1661-6. [QxMD MEDLINE Link].

77. Connolly SJ, Hallstrom AP, Cappato R, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg . Canadian Implantable Defibrillator Study. Eur Heart J. 2000 Dec. 21 (24):2071-8. [QxMD MEDLINE Link].

78. Goldenberg I, Barsheshet A, Laish-Farkash A, et al, for the Israeli Working Group on Pacing and Electrophysiology. Anemia and the risk of life-threatening ventricular tachyarrhythmias from the Israeli Implantable Cardioverter Defibrillator Registry. Am J Cardiol. 2017 Dec 15. 120 (12):2187-92. [QxMD MEDLINE Link].

79. Marchlinski FE, Deely MP, Zado ES. Sex-specific triggers for right ventricular outflow tract tachycardia. Am Heart J. 2000 Jun. 139 (6):1009-13. [QxMD MEDLINE Link].

80. Raitt MH, Connor WE, Morris C, et al. Fish oil supplementation and risk of ventricular tachycardia and ventricular fibrillation in patients with implantable defibrillators: a randomized controlled trial. JAMA. 2005 Jun 15. 293 (23):2884-91. [QxMD MEDLINE Link].

81. Neumar RW, Otto CW, Link MS, et al. Part 8: adult advanced cardiovascular life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2010 Nov 2. 122 (18 suppl 3):S729-67. [QxMD MEDLINE Link]. [Full Text].

82. [Guideline] Priori SG, Blomström-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J. 2015 Nov 1. 36 (41):2793-867. [QxMD MEDLINE Link]. [Full Text].

83. [Guideline] Piccini JP Sr, Allen LA, Kudenchuk PJ, et al, for the American Heart Association Electrocardiography and Arrhythmias Committee of the Council on Clinical Cardiology and Council on Cardiovascular and Stroke Nursing. Wearable cardioverter-defibrillator therapy for the prevention of sudden cardiac death: a science advisory from the American Heart Association. Circulation. 2016 Apr 26. 133 (17):1715-27. [QxMD MEDLINE Link]. [Full Text].

84. [Guideline] Priori SG, Wilde AA, Horie M, Cho Y, Behr ER, Berul C, et al. HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013. Heart Rhythm. 2013 Dec. 10 (12):1932-63. [QxMD MEDLINE Link].

85. O'Riordan M. Cardiac risks with antibiotics azithromycin, levofloxacin supported by VA data. Medscape Medical News. Available at http://www.medscape.com/viewarticle/821697. March 10, 2014; Accessed: March 15, 2014.

86. Chiu SN, Wu WL, Lu CW, et al. Primary ventricular tachycardia in paediatric population in a tertiary centre. Arch Dis Child. 2017 Dec. 102 (12):1137-42. [QxMD MEDLINE Link].

Author

Steven J Compton, MD, FACC, FACP, FHRS Director of Cardiac Electrophysiology, Alaska Heart Institute, Providence and Alaska Regional Hospitals

Steven J Compton, MD, FACC, FACP, FHRS is a member of the following medical societies: American College of Physicians, American Heart Association, American Medical Association, Heart Rhythm Society, Alaska State Medical Association, American College of Cardiology

Disclosure: Nothing to disclose.

Chief Editor

Jeffrey N Rottman, MD Professor of Medicine, Department of Medicine, Division of Cardiovascular Medicine, University of Maryland School of Medicine; Cardiologist/Electrophysiologist, University of Maryland Medical System and VA Maryland Health Care System

Jeffrey N Rottman, MD is a member of the following medical societies: American Heart Association, Heart Rhythm Society

Disclosure: Nothing to disclose.

Acknowledgements

David FM Brown, MD Associate Professor, Division of Emergency Medicine, Harvard Medical School; Vice Chair, Department of Emergency Medicine, Massachusetts General Hospital

David FM Brown, MD is a member of the following medical societies: American College of Emergency Physicians and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Steven A Conrad, MD, PhD Chief, Department of Emergency Medicine; Chief, Multidisciplinary Critical Care Service, Professor, Department of Emergency and Internal Medicine, Louisiana State University Health Sciences Center

Steven A Conrad, MD, PhD is a member of the following medical societies: American College of Chest Physicians, American College of Critical Care Medicine, American College of Emergency Physicians, American College of Physicians, International Society for Heart and Lung Transplantation, Louisiana State Medical Society, Shock Society, Society for Academic Emergency Medicine, and Society of Critical Care Medicine

Disclosure: Nothing to disclose.

Ian S deSouza, MD Assistant Professor, Department of Emergency Medicine, Kings County Hospital/SUNY Downstate Medical Centers

Ian S deSouza, MD is a member of the following medical societies: American Academy of Emergency Medicine

Disclosure: Nothing to disclose.

Brian Olshansky, MD Professor of Medicine, Department of Internal Medicine, University of Iowa College of Medicine

Brian Olshansky, MD is a member of the following medical societies: American College of Cardiology, American Heart Association, Cardiac Electrophysiology Society, and Heart Rhythm Society

Disclosure: Guidant/Boston Scientific Honoraria Speaking and teaching; Medtronic Honoraria Speaking and teaching; Guidant/Boston Scientific Consulting fee Consulting

Justin D Pearlman, MD, ME, PhD, FACC, MA Chief, Division of Cardiology, Director of Cardiology Consultative Service, Director of Cardiology Clinic Service, Director of Cardiology Non-Invasive Laboratory, Director of Cardiology Quality Program KMC, Dartmouth-Hitchcock Medical Center, Dartmouth Medical School

Justin D Pearlman, MD, ME, PhD, FACC, MA is a member of the following medical societies: American College of Cardiology, American College of Physicians, American Federation for Medical Research, International Society for Magnetic Resonance in Medicine, and Radiological Society of North America

Disclosure: Nothing to disclose.

Gary Setnik, MD Chair, Department of Emergency Medicine, Mount Auburn Hospital; Assistant Professor, Division of Emergency Medicine, Harvard Medical School

Gary Setnik, MD is a member of the following medical societies: American College of Emergency Physicians, National Association of EMS Physicians, and Society for Academic Emergency Medicine

Disclosure: SironaHealth Salary Management position; South Middlesex EMS Consortium Salary Management position; ProceduresConsult.com Royalty Other

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Che' Damon Ward, MD Staff Physician, Department of Emergency Medicine, State University of New York Health Science Center at Brooklyn

Che' Damon Ward, MD is a member of the following medical societies: American Academy of Emergency Medicine and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

When ventricular fibrillation occurs in an ICU the first person reaching the client should?

When ventricular fibrillation occurs in the CCU the first person reaching the client should quizlet?

What do you do for a patient in ventricular fibrillation?

What is the most effective treatment for a patient in ventricular fibrillation?